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ORIGINAL ARTICLE
DNA methylation signal has a major role in the response of
human breast cancer cells to the microenvironment
P Mathot1, M Grandin1, G Devailly2, F Souaze3, V Cahais4, S Moran5, M Campone3, Z Herceg4, M Esteller5,6,7, P Juin3, P Mehlen1
and R Dante1
Breast cancer-associated ﬁbroblasts (CAFs) have a crucial role in tumor initiation, metastasis and therapeutic resistance by secreting
various growth factors, cytokines, protease and extracellular matrix components. Soluble factors secreted by CAFs are involved in
many pathways including inﬂammation, metabolism, proliferation and epigenetic modulation, suggesting that CAF-dependent
reprograming of cancer cells affects a large set of genes. This paracrine signaling has an important role in tumor progression, thus
deciphering some of these processes could lead to relevant discoveries with subsequent clinical implications. Here, we investigated
the mechanisms underlying the changes in gene expression patterns associated with the cross-talk between breast cancer cells and
the stroma. From RNAseq data obtained from breast cancer cell lines grown in presence of CAF-secreted factors, we identiﬁed 372
upregulated genes, exhibiting an expression level positively correlated with the stromal content of breast cancer specimens.
Furthermore, we observed that gene expression changes were not mediated through signiﬁcant DNA methylation changes.
Nevertheless, CAF-secreted factors but also stromal content of the tumors remarkably activated speciﬁc genes characterized by a
DNA methylation pattern: hypermethylation at transcription start site and shore regions. Experimental approaches (inhibition of
DNA methylation, knockdown of methyl-CpG-binding domain protein 2 and chromatin immunoprecipitation assays) indicated that
this set of genes was epigenetically controlled. These data elucidate the importance of epigenetics marks in the cancer cell
reprogramming induced by stromal cell and indicated that the interpreters of the DNA methylation signal have a major role in the
response of the cancer cells to the microenvironment.
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INTRODUCTION
The tumor microenvironment is composed of a heterogeneous
population of non-neoplastic cells including immune cells,
vascular endothelial cells and ﬁbroblasts. The presence of cancer
cells leads to the appearance of phenotypically modiﬁed
ﬁbroblasts, which in turn reprogram tumor cells. The cross-talk
between these components and cancer cells promotes tumor
growth, metastasis,1 and impacts the response of tumors to anti-
cancer therapies.2–8
In breast tumors-activated ﬁbroblasts (cancer-associated ﬁbro-
blasts, CAFs) are the predominant stromal cell type.9 CAFs present
some characteristics of myoﬁbroblasts and express speciﬁc
markers including α-smooth muscle actin, vimentin, neuron glial
antigen-2 and ﬁbroblast-speciﬁc protein-1.10 CAFs secrete various
growth factors (including, ﬁbroblast growth factors, hepatocyte
growth factor, transforming growth factor-β1 and SDF-1/CXCL12),
cytokines (including, IL-6, Slit2, IL-8, IL-10, TNF-α, monocyte
chemoattractantprotein-1, leptin and interferon-β), proteases
and extracellular matrix components involved in tumor initiation,
progression and invasion of breast cancer.11–18 In vitro co-cultures
have underlined the importance of heterotypic interactions
among different cell types.19 For instance, the contribution of
CAFs to lapatinib resistance can be mediated by cell contact,7
whereas CAF culture supernatants are able to induce resistance
to RAF inhibitors in breast cancer cells.16,20 Soluble factors
secreted by CAFs and cancer cells are involved in many pathways
including inﬂammation, metabolism, proliferation and epigenetic
modulation,21 suggesting that CAF-dependent reprograming of
cancer cells affects a large set of genes.
Thus, paracrine signaling seems to have an important role in the
cross-talk between cancer cells and CAFs, and deciphering some
of these processes could lead to relevant discoveries with
subsequent clinical implications. In the present study, we have
investigated the mechanisms underlying the changes in gene
expression patterns associated with the cross-talk between cancer
cells and the stroma. Unexpectedly, we found that gene
expression changes induced by CAF-secreted factors were not
mediated through signiﬁcant DNA methylation changes. Never-
theless, CAF-secreted factors remarkably activate genes character-
ized by a high level of methylated CpGs on their regulatory region,
deﬁning a DNA methylation pattern of genes modulated by
stromal cell contents in human breast tumors. Our data put in
light the importance of epigenetic marks in the cancer cell
reprogramming induced by stromal cell.
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RESULTS
Identiﬁcation of stromal-dependent genes in human breast
tumors
To assess the mechanisms underlying the changes in gene
expression patterns associated with the cross-talk between cancer
cells and the stroma, primary cultures of stromal ﬁbroblasts were
established from three primary inﬁltrating ductal carcinoma (CAF-8,
CAF-11 and CAF-15) and from one primary inﬁltrating lobular
carcinoma (CAF-12); the anatomopathological characteristics of the
breast tumors are shown in Supplementary Table S1. Western blot
analysis of the cultured ﬁbroblasts (CAF-8, CAF-11, CAF-12 and
CAF-15) indicated that they strongly expressed the CAF markers,
alpha smooth muscle actin and vimentin,10 at a similar level at
different passages, whereas, as expected, the negative marker
E-cadherin remained undetected (Supplementary Figure S1). CAF
cultures were also characterized by their impact on cancer cell
morphology. When cultured for 48 h in CAF culture supernatant
(CAF-CM), the SKBR3 and the AU565 breast cancer cell lines
underwent morphological changes, adopting a spindle-like shape
with actin reorganization and an increase in size (Figure 1a),
consistent with other breast cancer cell lines cultured in CAF culture
supernatants22 or treated with transforming growth factor-β.23
To identify gene expression changes induced by CAF-secreted
factors, the impact of CAF-CM on the transcriptomes of SKBR3 and
AU565 breast cancer cell lines was investigated by high-
throughput sequencing of polyadenylated RNA (RNAseq). Heat-
maps depicting fold changes in gene expression induced by CAF-
CMs indicated that conditioned media from the four primary
cultures of CAF have similar effects on gene expression in both cell
lines (Figure 1b). Combining data obtained using CAF-8, CAF-11,
CAF-12 and CAF-15, we identiﬁed 558 and 732 genes upregulated
(fold change (FC)⩾ 2, q-valueo0.05), respectively, in SKBR3 and
AU565 cells exposed to CAF-CMs (Supplementary Figure S2).
Furthermore, the fold changes induced by CAF-CMs were highly
correlated between each other (Pearson correlation coefﬁcient, r,
ranging from 0.902 to 1, Supplementary Table S2).
Similarities between gene induction by CAF were also observed
between cell lines, as 67% of genes upregulated upon exposure to
CAF-CMs in SKBR3 cells were also upregulated in AU565
(Supplementary Figure S3A). These data led to the identiﬁcation
of a set of 372 genes upregulated (FC⩾ 2, in both cell lines) by
CAF-secreted factors in both cell lines (‘upregulated genes’;
Supplementary Table S5). Concomitantly we identiﬁed a set of
3479 genes unaffected by CAF-secreted factors (0.8⩽ FC⩽ 1.2, in
both cell lines), in SKBR3 and AU565 cell lines (‘unaffected genes’;
Supplementary Table S5). ‘Upregulated genes’ were investigated
for their representation in KEGG pathways by WebGestalt.24 KEGG
pathways enriched in this set of genes included several pathways
known to be involved in the cross-talk between CAFs and cancer
cells, metabolic pathways, cytokine–cytokine receptor interaction,
pathways implicated in cancer, the Jak-STAT signaling pathway,
and the MAPK signaling pathway (Supplementary Figure S3B).
These in vitro results identiﬁed groups of genes modulated by
CAF-secreted factors in breast cancer cell lines. In order to
investigate the potential physiological signiﬁcance of this ﬁnding,
we examined their expression according to the level of stromal
cells present in human breast tumors from samples available
through The Cancer Genome Atlas (TCGA). The stromal cell
contents of the tumors were evaluated using the stromal
ESTIMATE score,25 (data available at bioinformatics.mdanderson.
org/estimate). Among the 372 ‘upregulated genes’, only 6 also
belonged to the gene list of stromal signature.25 Tumors were
subdivided in two groups, ‘high stromal score’ (positive score
values, n= 750) and ‘low stromal score’ (negative score values,
n= 350). Heatmap depicting the expression level of the set of
‘upregulated genes’ in the two groups of tumors (high/low
stromal score) indicated that the set of ‘upregulated genes’ was
expressed at a higher level in the group of tumors with high
stromal cell content than in the group with low stromal cell
content (Figure 1c). Conversely, the expression levels of the
‘unaffected genes’ were similar in the two groups of tumors
(Figure 1c).
Then, these differences were quantiﬁed using the mean
expression levels of the different groups of genes: ‘upregulated
genes’, ‘unaffected genes’ and ‘other-genes group’ (genes
not included in the two later categories) (Figure 1d). For the set
of ‘upregulated genes’, the difference between means observed
between the two groups of tumors was statistically signiﬁcant (two-
tailed unpaired Student’s t-test, Po0.0001, difference between
means in RSEM (diff-mean-RSEM)=218.2, coefﬁcient of variation
(CV=24.9%). In contrast, very small differences were observed
between the two groups of tumors for the ‘unaffected genes’ (diff-
mean-RSEM= –57.50, CV=6.6%) and for the ‘other-genes group’
(diff-mean-RSEM=17.65, CV=7.2%) (Figure 1d). Furthermore, the
mean expression level (ranging from 563 to 3125 RSEM) of the
‘upregulated genes’ was positively correlated with the stromal score
(Pearson’s r=0.36, P=1.3 ×10− 33) (Figure 1e). This positive correla-
tion was not observed for the ‘unaffected genes’, their mean
expression level varied in a narrow range (from 1093 to 1793 RSEM)
and was even negatively correlated (Pearson’s r=− 0.40,
Po1× 10−100) with the stromal score (Figure 1f).
When the human breast tumors were subdivided according
to the main tumor types found in the TCGA databank (invasive
lobular carcinoma and invasive ductal carcinoma samples),
this correlation seemed to be stronger (Pearson’s r=0.49) in invasive
lobular carcinoma than in invasive ductal carcinoma (Pearson’s
r=0.33) (Supplementary Figure S4). Although this difference may be
due to sample sizes (n=182 and n=752), these data may suggested
that the response to stromal cell content might be also dependent
on the tumor type. Taken together, these results identiﬁed groups of
genes, which are modulated by CAF-secreted factors in vitro and
presenting an expression level dependent on the presence of
stromal cells in human breast tumors.
Gene upregulation upon CAF-secreted factors occurs in the
absence of DNA methylation changes
Epigenetic modiﬁcations seem to have a crucial role in the cross-
talk between cancer cells and the stroma.26,27 To investigate the
existence of DNA methylation changes associated with genes
modulation induced by CAF-secreted factors, DNA methylation
levels, at key genomic regions, were determined using the
MethylationEPIC (EPIC) BeadChip technology, which covers over
850 000 CpG sites. We observed ﬁrst that DNA methylations levels,
at key genomic regions, were different in SKBR3 and AU565 cells
(Supplementary Figure S5). CpGs were annotated according to the
manifest provided with the Inﬁnium MethylationEPIC and
classiﬁed into three different groups: ‘TSS regions’ (TSS1500,
0–1500 bases upstream of transcription start site (TSS), ‘shore
regions’ (shore, 0–2 kb from CpG island) and ‘shelf regions’ (shelf,
2–4 kb from CpG island). Differential methylation was not
observed on the TSS regions of the ‘upregulated genes’ in
SKBR3 and AU565 cells grown in two different CAF-CMs
(Figure 2a). Data obtained for ETV7, STAT5A, SOX9, KSR1, PDK4
and PARP14 illustrate this analysis (Figure 2b). Furthermore, using
ChAMP software, we did not detect signiﬁcant change at the
850 000 CpGs analyzed, in cell lines grown in CAF-CMs compared
with control cells. Concomitantly, in human breast tumor we did
not detect differential methylation of ‘upregulated genes’ in
tumor presenting high stromal score compare with tumor
presenting low stromal score (Figure 2c). Although we,28–30 as
many other colleagues, have observed that methylation changes
may have a major role in carcinogenesis, our data showed that
genes induced by stromal cells was unexpectedly not mediated
through DNA methylation changes.
DNA methylation patterns at genes modulated by CAF
P Mathot et al
2
Oncogenesis (2017), 1 – 12
SK
BR
3
NT CAF-CM
AU
56
5
Upregulated 
genes
Downregulated 
genes
CAF-CMs CA
F-
8
CA
F-
15
CA
F-
11
CA
F-
12
-1
2
1
0
Log2 (FC) 
relative to 
untreated cells
SKBR3
CAF-CMs CA
F-
8
CA
F-
15
CA
F-
11
CA
F-
12
AU565
-2
Ex
pr
es
sio
n 
(R
SE
M)
4000
3000
2000
1000
****
****
****
Low stromal score
High stromal score
Upregulated genes 
1000 2000 3000
  -1000
0
St
ro
m
al
 s
co
re
2000
Pearson r = 0.36
P value = 1.3x10 - 33  -2000
1000
Expression (RSEM)
Unaffected genes 
1000 2000 3000
  -1000
0
St
ro
m
al
 s
co
re
2000
Pearson r = -0.40
P value < 1x10 -100 -2000
1000
Expression (RSEM)
Ex
pr
es
sio
n 
le
ve
l-L
og
2 
(R
SE
M)
Up
re
gu
la
te
d 
ge
ne
s
Stromal score: Low      High
1
0.5
0
-0.5
-1
Ex
pr
es
sio
n 
le
ve
l-L
og
2 
(R
SE
M)
Un
af
fe
ct
ed
 g
en
es
Stromal score: Low      High
Figure 1. Identiﬁcation of stromal-dependent genes in human breast tumors. (a) Breast cancer cell lines SKBR3 and AU565 treated with CAF-11
CM or control medium for 48 h were stained for F-actin. Nuclei were visualized using DAPI staining in blue. Representative images, scale bars,
50 μm. (b) Heatmaps from RNAseq data of SKBR3 and AU565 cell lines. Genes were classiﬁed according to their expression levels in cells
treated with CAF-CMs normalized by their expression in control cells. (c) Heatmap depicting expression level of genes modulated by CAF-
secreted factors identiﬁed in vitro in function of human breast tumors stromal score; left panel: genes upregulated by CAF-secreted factors
(median centering, n= 1042); right panel: genes unaffected by CAF-secreted factors (median centering, n= 1042). (d) Mean expression level of
genes modulated by CAF-secreted factors identiﬁed in vitro, in human breast tumors as a function of the tumor stromal score. (****Po0.0001,
two-tailed unpaired Student’s t-test. Error bars= s.e.m). (e) Linear regression curve presenting the relationship between the mean expression
level of genes upregulated by CAF-secreted factors identiﬁed in vitro and the tumor stromal score. (f) Linear regression curve presenting the
relationship between genes unaffected by CAF-secreted factors identiﬁed in vitro and the tumor stromal score.
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Figure 2. Gene upregulation upon CAF-secreted factors occurs in the absence of DNA methylation changes. (a) Violin plots depicting the level
of DNA methylation (β value) at TSS1500 regions of ‘upregulated genes’. The level of DNA methylation of these genes was analyzed in SKBR3
and AU565 cells treated with CAF-11 CM, CAF-15 CM or control medium (NT) for 48 h. (b) Genome coverage of DNA methylation in NT cells
(gray) or in cells treated with CAF-11 CM (blue) at six genomic locations. Scales (β values); Genes in black and CpG islands in red. (c) Mean DNA
methylation level (β values) at TSS1500 regions of ‘upregulated genes’ in human breast tumors in function of their tumor stromal score. (NS
P⩾ 0.05, two-tailed unpaired Student’s t-test).
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DNA methylation patterns of genes modulated by CAF-secreted
factors
We observed that the TSS regions of ‘upregulated genes’ were
signiﬁcantly more methylated (Po0.0001, two-tailed unpaired
Student’s t-test) than the TSS regions of ‘unaffected genes’, in
SKBR3 and AU565 cells (Figure 3a). Signiﬁcant hypermethylation
of ‘upregulated genes’ (Po0.0001, two-tailed unpaired Student’s
t-test) was also observed for shore regions (Figure 3a), whereas
shelf regions that are more distant from regulatory regions did not
exhibited this characteristic (Figure 3a). This hypermethylation was
symmetrically distributed around the TSS for both cell lines
(Figure 3b). Furthermore, in breast tumor, as observed in cell lines,
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the set of ‘upregulated genes’ exhibited hypermethylations on
their TSS regions when compared with the TSS region of
‘unaffected genes’ or the TSS region of the ‘other-genes groups’
(two-tailed unpaired Student’s t-test, Po0.0001) (Figure 3c).
Heatmap depicting the TSS methylation level of ‘upregulated
genes’ on human breast tumors revealed a relative homogeneity
among the 839 patients analyzed (Figure 3d). Moreover, heatmap
depicting the mean methylation level of these ‘upregulated
genes’ in tumor tissue and normal tissue in paired normal/tumoral
samples (n= 75) showed similar DNA methylation levels of these
genes in tumor when compared with their normal counterpart,
indicating that this DNA methylation pattern was not induced by
the tumor but, for most of them, characterized these genes
(Figure 3e).
Then, as a control, we investigated the relationship between
genes harboring an expression level positively correlated with the
stromal cell content of the tumors and their methylation statue at
TSS regions, from the TCGA database. TGCA breast cancer cohort
was subdivided in genes correlated (Pearson r⩾ 0.3), or not
correlated (Pearson ro0.3), with the stromal cell content of the
tumors. We observed that DNA methylation levels at TSS regions
were higher in the group of correlated genes (% of methylation:
median value: 0.35; N= 1066 genes) than in the group of genes
not-correlated (median value: 0.21; N= 14904). To avoid potential
biases due to different expression levels between the two groups,
we also limited our analysis to genes with similar expression levels
(2 ×median⩽ RSEM values⩾ 0.5 ×median). Differential methyla-
tion levels between the two groups were still observed (median
value: 0.30, N= 736 versus median value: 0.10, N= 8647 in the
group genes correlated or not correlated, respectively) (Figure 3f),
whereas their mean expression level was not signiﬁcantly different
(two-tailed unpaired Student’s t-test, P= 0.75), (Figure 3g).
This result indicate that CAF-secreted factors but also stromal
content of the tumor remarkably activate genes characterized by a
high level of methylated CpGs on their regulatory region, deﬁning
a DNA methylation pattern of genes modulated by stromal cell
contents in human breast tumors. Thus, this DNA methylation
pattern of genes upregulated by CAF-secreted factors suggests
that DNA methylation was involved in their transcriptional
regulation.
Involvement of DNA methylation in the response to CAF-secreted
factors
To gain further insight into the association between these DNA
methylation patterns and gene expression, SKBR3 and AU565 cells
were treated with decitabine (DAC), an inhibitor of DNA
methylation. Analysis of CpG methylation using the EPIC BeadChip
approach indicated that DAC treatment resulted in an efﬁcient
demethylation of TSS regions (Po0.0001, two-tailed unpaired
Student’s t-test) as the global hypomethylation levels, at the CpG
represented on these beads, were estimated at 18% and 27% for
SKBR3 and AU565 cells, respectively (Supplementary Figure S6).
Furthermore, RNAseq experiments, indicated that a large
proportion (70% and 49%, in SKBR3 and AU565 cells,
respectively) of genes upregulated by CAF-CMs were also
upregulated upon DNA methylation inhibition by DAC (FC⩾ 2,
adjusted Po0.05), whereas DAC treatments downregulated a very
small fraction (0.4% and 2.5%, in SKBR3 and AU565 cells,
respectively) of this set of genes (Figure 4a). Moreover, a very
low proportion (0.9% and 1.3%, in SKBR3 and AU565 cells,
respectively) of genes unaffected by CAF-CMs were upregulated
upon DAC treatment (Supplementary Figure S7), suggesting that
DNA methylation was involved in the regulation of a large part of
‘upregulated genes’.
The potential involvement of DNA methylation in the response
to CAF-secreted factors was investigated for speciﬁc genes in both
cell lines. For ITGB6, STAT5A, MUC20, SERPINA3, SAA1 and FHL2,
DAC treatment reduced their response to CAF-CM (Figure 4b). This
result indicates that CAF-mediated gene upregulation and
demethylation-dependent upregulation (induced by DAC) did
not produce a cumulative effect. This result suggests that
presence of methylated CpGs seems to have an important role
on the upregulation induced by CAF-secreted factors. As the
upregulation of these hypermethylated genes was not mediated
through a demethylation induced by CAF-secreted factors, it
might be dependent on the modulation of proteins involved in
the interpretation of their DNA methylation.
Methyl DNA-binding protein MBD2 deposition at genes
modulated by CAF-secreted factors
Among the proteins involved in the repression of methylated
genes, many studies have shown that the methyl-CpG-binding
domain proteins (MBD) have a major role in translating DNA
methylation into gene repression.31–33 These proteins recognize
methylated CpG sites independently of their surrounding
sequences and recruit repressor complexes at their binding sites.
The MBD2, a member of the MBD protein family, regulates
multiple aspects of cell differentiation and function, including
immune iPS reprogramming,34 immune response35 and
cancer.36–38 We thus investigated the impact of MBD2 depletion
on the set of ‘upregulated genes’. MBD2 knockdown by transient
transfection with a siRNA targeting MBD239 led to a 86% and 87%
reduction of MBD2 mRNA in SKBR3 and AU565 cells, respectively,
whereas the other members of the MBD family (MeCP2, MBD1 and
MBD4) were not affected (Supplementary Table S3). This inhibition
was also observed at the protein level (Figure 5a).
We identiﬁed by RNAseq 292 and 459 genes speciﬁcally
upregulated in SKBR3 and AU565 cells, respectively, following siMBD2
treatments compared with scrambled control siRNA. A substantial
part of these genes were also upregulated by CAF-secreted factors,
16% and 27% in SKBR3 and AU565, respectively (Figure 5b).
Furthermore, the fold changes in gene expression observed upon
MBD2 depletion were positively correlated with the fold changes
induced by CAF-CMs (Figures 5c and d) (Pearson’s r=0.27 and
r=0.42, P=0.000017 and P=1.4×10−12 for SKBR3 and AU565
cells, respectively), indicating that a fraction of genes upregulated
Figure 3. DNA methylation of genes modulated by CAF-secreted factors. (a) Violin plots depicting the level of DNA methylation (β values) of
‘upregulated genes’ or ‘unaffected genes’ in SKBR3 and AU565 cell lines; diamond, median value; DNA methylation level at TSS1500, Shore
and Self-regions. (****Po0.0001, two-tailed unpaired Student’s t-test). (b) DNA methylation level (β values) of ‘upregulated genes’ or
‘unaffected genes according to their distance to TSS, in SKBR3 and AU565 cell lines. (c) Mean DNA methylation levels at the TSS1500 region of
genes modulated by CAF-secreted factors identiﬁed in vitro, in human breast tumors. (****Po0.0001, two-tailed unpaired Student’s t-test).
(d) Heatmap depicting the methylation level at TSS1500 regions of ‘upregulated genes’, in human breast tumors (n= 839 patients).
(e) Heatmap depicting the methylation level at TSS1500 regions of ‘upregulated genes’ in paired normal/tumoral sample, in the 75 patients
analyzed. (f) Violin plots depicting the level of DNA methylation (β values) of genes with an expression positively correlated (‘Correlated’,
Pearson r⩾ 0.3, n= 736) or not correlated (‘Not-correlated’, Pearson ro0.3, n= 8647) with the stromal cell content of the tumors; diamond,
median value; DNA methylation level at TSS1500 (****Po0.0001, two-tailed unpaired Student’s t-test). (g) Violin plots depicting the expression
level of genes Correlated or Not-correlated with the stromal cell content of the tumors, diamond, median value; Expression level (NS=not
signiﬁcant, P= 0.75, two-tailed unpaired Student’s t-test).
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by CAF-secreted factors are regulated by MBD2 through their DNA
methylation pattern. Moreover, MBD2 deposition at 17 genes,
upregulated upon MBD2 depletion and treatment with CAF-CMs,
was validated by chromatin immunoprecipitation assays (Figures 5e
and f) from both cell lines grown in control medium. These data
indicated that the methyl-dependent repressor MBD2 targets a part
of genes upregulated by CAF-secreted factors. Furthermore, chroma-
tin immunoprecipitation (ChIP) assays indicated MBD2 enrichments
were reduced at several upregulated genes, in cell SKBR3 and AU565
cells grown in presence of CAF-secreted factors (Figures 5g and h).
Taken together, these data suggest that dynamic MBD2 deposition
across methylated DNA regions was associated with the modulation
of gene expression by the CAF.
DISCUSSION
It is well-recognized that some genes are speciﬁcally expressed by
normal cell of the tumor microenvironment upon the presence of
tumor cells.40–44 Concomitantly, the importance of stromal cells
for tumor progression has also been established,17,43 although the
stroma has been reported to limit cancer progression mainly
during the ﬁrst steps of the oncogenic process.45 Dozens of factors
secreted by CAFs have now been identiﬁed and their role in
cancer cell plasticity is widely acknowledged.21,46 The mechanisms
underlying the changes in gene expression patterns associated
with the cross-talk between cancer cells and the stroma remain an
ongoing ﬁeld of research.
Genetic modiﬁcations do not seem to have an important role in
the phenotypic modiﬁcations observed in ﬁbroblasts upon activa-
tion by cancer cells,47–49 however, these phenotypic modiﬁcations
are conserved over several passages during in vitro cultivation of
CAFs. Epigenetic modiﬁcations should, therefore, have a major role
in the cancer–stroma cross-talk.48 Epigenetic modiﬁcations do not
occur only in CAFs but can be induced in cancer cells by CAF
interactions because many CAF-secreted factors are involved in
epigenetic pathways. For example, the CAF-secreted factor
transforming growth factor-β,22,50,51 mediates epigenetic switches
through SOX4 activation, which in turn modulates EZH2, a histone
methyltransferase, in cancer cells.52 Furthermore, transforming
growth factor-β treatments may induce genome-wide changes in
DNA methylation, in liver cancer cell lines.53 Epigenetic players, such
as miRNAs,54 also contribute to the maintenance of an invasive,
cancer initiating cell phenotype. For instance, loss of Let7 is also
expected to induce HMGA2, a regulator of the chromatin
remodeling of stemness traits in transformed cells.55
Taken together these data indicate that epigenetic markers
could have a central role in the tumor–stroma cross-talk.
Consistently, inhibition of DNA methylation by exposure to DAC
upregulated a large proportion (~60%) of genes upregulated by
CAF-secreted factors, identiﬁed in a model based on two human
breast cancer cell lines.
The analysis of DNA methylation using the Inﬁnium Methylatio-
nEPIC beadChip technology, which interrogates 850 000 CpGs, also
highlighted the importance of epigenetic marks. The potential
regulatory regions (TSS and shore regions) of genes modulated
by CAF-secreted factors were hypermethylated when compared
with genes unresponsive to these stimuli. We did not detect
signiﬁcant differentially methylated CpG between cells grown in
CAF conditioned medium and cells grown in control medium,
indicating that gene upregulation driven by CAF-secreted factors
was not mediated through changes in DNA methylation. Our results
provide evidence that CAF-secreted factors induced phenotypic
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Figure 5. Methyl DNA-binding protein MBD2 deposition at genes modulated by CAF-secreted factors. (a) Western blot analysis of MBD2
proteins in SKBR3 and AU565 cells treated with siRNA targeting MBD2. (b) Venn diagram of genes upregulated by CAF-CMs compared with
genes upregulated by MBD2 siRNA (Po0.0001, hypergeometric test). (c) Linear regression curve presenting the relationship between the fold
change in gene expression induced by CAF-CMs and siRNA targeting MBD2 in SKBR3 and (d) in AU565. (e) Chromatin immunoprecipitation
mapping MBD2-biding sites at the 5’ end regions of genes upregulated by CAF-secreted factors in SKBR3 and (f) in AU565. (*Po0.05;
**Po0.01; ****Po0.0001, two-tailed unpaired Student’s t-test. Error bars= s.e.m). (g) Chromatin immunoprecipitation assays of MBD2
enrichment at the 5’ end regions of genes upregulated by CAF-secreted factors in SKBR3 treated with CAF-8-CM (CAF-CM), NT (not treated);
and (h) in AU565. (*Po0.05; **Po0.01; ****Po0.0001, two-tailed unpaired Student’s t-test. Error bars= s.e.m).
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changes in cancer cell lines without substantial DNA methylation
changes. In line with these data, it has been reported that
transdifferentiation of B cell to macrophage can occur without
DNA methylation changes.56 These ﬁndings suggest that
CAF-secreted factors can induce changes in the interpretation of
this epigenetic mark to activate or repress the expression of
key genes.
The model used allowed us to isolate the effects of
CAF-secreted factors from those occurring during heterotypic
interactions, which occur in human tumors. However, we cannot
exclude that changes in DNA methylation in cancer cells could be
induced by contact with stromal cells in human breast tumors.
Alternatively, our model did not allow the identiﬁcation of the
genes undergoing CAF-dependent changes in methylation as cells
were grown in CAF culture supernatant for a relatively short time.
However, the treatments were long enough to alter the expression
of many genes, in the AU565 and SKBR3 breast cancer cell lines,
suggesting that long-term DNA methylation changes (including
more methylation in certain regions associated with gene
upregulation) might more important in locking in transcriptional
changes that initiating them. Nevertheless, when clinical breast
cancer specimens were classiﬁed according to their stromal cell
contents (TCGA databank), the methylation patterns of the genes
upregulated by CAF-secreted factors did not differ in tumors,
exhibiting a high stromal cell content from those with a low
stromal cell content.
This epigenetic mark is linked to transcriptional control by
various mechanisms. DNA methylation may impair the direct
binding of transcription factors to their targets and, in turn, may
lead to transcriptional downregulation.57–61 More recently, it has
been shown that some transcriptions factors bind to methylated
sequences, and for some of them the methylation status of
speciﬁc CpGs participates in deﬁning their binding sites.62
Pioneering studies, from in vitro transcription assays, have
established that DNA methylation does not inhibit transcription
per se and suggest that proteins associating DNA sequences play
an important role in the repression of methylated templates.63
Several families of proteins that recognize methylated DNA with
no or weak sequence speciﬁcity have been identiﬁed.31,64 Their
methyl DNA-binding domain has been used to deﬁne three major
families of proteins,32,65 among them the MBD exhibit weak or no
speciﬁcities for sequences surrounding methylated CpGs.65–67
Nevertheless, these proteins are involved in many cellular
processes. For example MBD2 is a crucial player in differentiation,
carcinogenesis, and immunology, and has an important role in the
repression of methylated genes, whereas this protein may also act
as a transcriptional activator for some genes.68,69 Speciﬁc MBD2
deposition occurs at genes downregulated during the in vitro
transformation of immortalized human mammary cells and for
~ 10% of them this speciﬁc deposition is not driven by changes in
DNA methylation but by the redistribution of MBD2 across
methylated regions.39
In the model used in the present study, MBD2 depletion
upregulated ~ 20% of the genes upregulated by CAF-CMs and
chromatin immunoprecipitation (ChIP) experiments have vali-
dated the presence of MBD2 at the 5’ end of the 17 genes
analyzed. Although these assays were not quantitative enough to
monitor potential changes in MBD2 deposition by ChIPseq, ChIP
assays indicated that CAF-CMs can reduce MBD2 deposition at
several upregulated genes, in SKBR3 and AU565 breast cancer cell
lines. A DNA methylation pattern was associated with the genes
modulated by CAF-secreted factors, whereas these transcriptomic
changes were not associated with direct changes in DNA
methylation. These data suggest that MBD2, and other proteins
recognizing methylated sequences, may be involved not only in
the control of these genes but also in the transcriptomic changes
observed upon CAF-secreted factors treatments.
Combining the data obtained from the different cell lines
and CAF media used, we identiﬁed 372 genes upregulated by
CAF-CMs. Many of these genes belong to pathways associated
with carcinogenesis and include transcription factors (STAT5A,
ETV7, ETV6, SOX4 and SOX9, for example) playing an important
role in oncogenesis. In clinical breast tumor specimens, the group
of genes identiﬁed from cell line models harbored an expression
positively correlated with the stromal cell content of the tumors
(TCGA databank, n= 1100), suggesting that these genes were also
modulated by the microenvironment in human breast tumors.
Furthermore, the stromal cell contents of the tumors did not
inﬂuence the expression level of genes unaffected (0.8⩽ FC⩾ 1.2)
by CAF-secreted factors. Taken together, these data suggested
that the in vitro model, used in this study, mimicked some
characteristics of the cross-talk between tumor cells and stroma,
and that the genes identiﬁed were involved in the physiopathol-
ogy of human breast tumors. A DNA methylation pattern, similar
to that observed in the AU565 and SKBR3 cell lines, deﬁned the
group of stroma-upregulated genes, as they were hypermethy-
lated at their TSS regions compared with the ‘unaffected genes’ or
to the ‘other-genes’ groups. Taken together these data suggest
that the DNA methylation mark may impact their CAF-dependent
expression in human breast tumors. In summary, our study
demonstrates that CAF-secreted factors but also stromal content
of the tumor remarkably activated speciﬁc genes characterized by
a DNA methylation pattern. These data provide new insights for
the identiﬁcation of molecular events deﬁning the responsiveness
of genes to stromal cell contents of human tumors. These ﬁndings
might have clinical implications; the targeting of methylation-
dependent mechanisms controlling gene expression may repre-
sent a new strategy for impacting the effects of stroma on cancer
cell plasticity.
MATERIALS AND METHODS
Tissue specimens and cultures
Human breast cancer cell lines AU565 and SKBR3 obtained from the
American Type Culture Collection were cultured in RPMI-1640 medium
(Life Technologies) and McCoy's 5a medium (Life Technologies, Saint-
Aubin, France) supplemented with 10% fetal bovine serum (Lonza, Basel,
Switzerland) and 1% penicillin/streptomycin (InVitrogen, Carlsbad, CA,
USA). After an initial screening using different breast cancer lines (MDA-
MB-231, MCF7, T-47D, BT20, MDA-MB-157, SKBR3 and AU565), the AU565
and SKBR3 cell lines were chosen for further studies because they
exhibited the most important morphological changes in presence of CAF-
secreted factors. Immortalized human mammary epithelial cells were
kindly provided by Dr Anne-Pierre Morel (CRCL, Lyon, France) and cultured
as previously described.70 Primary cultures of breast CAFs were kindly
provided by Dr Fréderique SOUAZE (CRCNA, Nantes, France) and cultured
in DMEM-F12 (Life Technologies) supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin. Fresh human mammary samples
were obtained from chemotherapy naive patients with invasive carcinoma
after surgical resection at the Institut de Cancérologie de l’Ouest, René
Gauducheau, Nantes, France. All procedures involving patient specimens
were approved by the local institutional review boards and all research was
carried out in accordance with the Helsinki declaration. CAF samples were
obtained with informed consent and human ethics approval from Institut
de Cancérologie de l’Ouest (Nantes, France). CAFs were used in the
experiments at less than eight passages, and their characteristics are
presented in Supplementary Table S1. Cell lines and CAF cultures were
tested for mycoplasma monthly using the MycoAlert Mycoplasma
Detection Kit (Lonza). To prepare CAF-CM, CAFs were cultured for 48 h
in DMEM-F12 supplemented with 1% fetal bovine serum, collected and
then centrifuged for 10 min at 1000 rounds per minute to remove cell
debris.
Treatments
For the CAF-CM treatment, cells were seeded at 1.105 per well in six-well
plates. The following day, cells were cultured in CAF-CM for 48 h. For MBD2
siRNA experiments, cells were seeded at 3.105 per well in six-well plates.
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The day after, cells were transfected with 100 pmol of MBD2-targeting
siRNA (siMBD2; sense: 5′-GGAGGAAGUGAUCCGAAAdTdT-3′)39 or control
siRNA (Sigma-Aldrich, MISSION siRNA Universal Negative Controls #1) using
RNAiMAX (Sigma-Aldrich, Saint-Quentin-Fallavier, France) as speciﬁed by
the manufacturer’s instructions. Cells were collected 72 h after treatment
initiation. For the DAC treatment, cells were seeded at 1.105 per well in six-
well plates. The following day, cells were treated daily with 10 μM of DAC
(Sigma-Aldrich) for 3 days and were then collected.
Immunoﬂuorescence staining
Cells were seeded onto a Nunc Lab-Tek Chamber Slide system (Sigma-
Aldrich), and cultured for 48 h prior to their ﬁxation in 3.7% paraformalde-
hyde for 20 min. Cells were permeabilized in PBS 1 × 0.1% Triton X-100 for
20 min and incubated with the ﬁlamentous actin (F-actin) dye (Phalloidin,
Fluorescein Isothiocyanate Labeled, Sigma-Aldrich) for 1 h. The cell nuclei
were counterstained with 4’,6-diamidino-2-phenylindole, dihydrochloride.
Expression analysis
Total RNA was extracted using the NucleoSpin RNA kit (Macherey-Nagel,
Hoerdt, France) following the manufacturer’s instructions. RNA purity,
integrity and quantiﬁcation were assessed using agarose gel-
electrophoresis and analyzed on a NanoDrop 1000 (Thermo Scientiﬁc,
Courtaboeuf, France). For RNAseq experiments, pools of three indepen-
dent experiments were sent for high-throughput sequencing to Integra-
Gen and each experiment was conducted in duplicate. For quantitative
real‐time PCR (qPCR), each experiment was carried out in triplicate, 1 μg of
RNA was reverse‐transcribed, using the iScript cDNA Synthesis Kit (Bio‐
Rad). Quantitative-PCR was performed using a Mini opticon (Bio‐Rad) and
the IQ SYBR Green supermix (Bio‐Rad, Marnes-la-Coquette, France). Gene
expression proﬁles were validated using two standard housekeeping
genes, PBGD and GAPDH. Primer sequences are listed in Supplementary
Table S4.
Immunoblotting
Cells were lysed in RIPA Buffer, lysates were sonicated and heated at 95 °C
for 5 min. After electrophoresis and transfer, membranes were incubated
either with anti-alpha smooth muscle actin (Abcam, ab7817, Paris, France),
anti-vimentin (Abcam, ab92547), anti-E-cadherin (BD Biosciences, 610181,
Le Pont-de-Claix, France), anti-MBD2a,b (Sigma-Aldrich, RA-18) or anti-
HPRT (Abcam, ab10479) antibodies.
MBD2 ChIP
MBD2 ChIP was performed as previously described.71 Sheared chromatin
(with a mean fragment length between 300 and 500 bp) was obtained by
sonication of formaldehyde crosslinked nuclei. ChIP was then performed
with an antibody against MBD2a,b (Sigma-Aldrich, RA-18) using the ChIP
Assay Kit (Merck Millipore, Molsheim, France) as speciﬁed by the
manufacturer’s instructions. Precipitated DNA was puriﬁed using the
NucleoSpin Gel and PCR Clean-up kit, (Macherey-Nagel) according to the
manufacturer’s protocol ‘DNA clean-up of samples containing SDS’. Input
and bound fractions of DNA were assayed by ﬂuorometry (Qubit 2.0, Life
Technologies). Enrichment in the bound fraction, compared to the input,
was measured by qPCR for several genes including one positive (pos-Ctrl)
and one negative control (neg-Ctrl), using iQ SYBR Green supermix
(BioRad, Marnes-la-Coquette, France). The pos-Ctrl was located at the
BRCA1-NBR2 locus, as this region was methylated in all samples analyzed so
far and associated with MBD2 (Auriol et al.71; Magdinier et al.72), whereas
the neg-Ctrl was a CpG-free region located on chromosome 16 q23.3.
Primer sequences are listed in Supplementary Table S4.
Inﬁnium MethylationEPIC beadChip
Genomic DNA was extracted from cell lines using the QIAmp DNA Mini Kit
(Qiagen, Courtaboeuf, France). DNA methylation analysis was subsequently
performed for duplicate experiments using the Inﬁnium MethylationEPIC
Kit (Illumina, Paris, France) according to the manufacturer’s instructions.73
Statistical and database analyses
For RNAseq analysis, reads were aligned using TopHat2ref.74 on the UCSC
Homo sapiens hg19 genome. Differential expression was assessed using
Cuffdif.75
KEGG Analyses were performed using the WEB-based Gene SeT AnaLysis
Toolkit (WebGestalt).24 For the Inﬁnium MethylationEPIC beadChip
analysis, the raw data obtained from the 850 K arrays were processed
from the IDAT ﬁles with the ChAMP pipeline.76 For TCGA analysis, data
were downloaded, assembled and processed using TCGA-Assembler77
(data download on December 2014). The list of analyzed genes is shown in
Supplementary Table S5. Subsequent analyses were performed with the R
statistical software v 3.3.1 and GraphPad Prism software.
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gene expression omnibus repository GSE95462. Private link for the
reviewer until acceptance of the manuscript: https://www.ncbi.nlm.nih.
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